Abbott Laboratories ABT
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.46% | 13.02% | 7.78% | 4.42% | 6.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.46% | 13.02% | 7.78% | 4.42% | 6.90% |
| Cost of Revenue | 10.90% | 9.70% | 9.44% | 0.68% | 8.02% |
| Gross Profit | 17.33% | 15.59% | 6.52% | 7.42% | 6.01% |
| SG&A Expenses | 41.47% | 31.27% | 22.89% | 7.41% | 5.18% |
| Depreciation & Amortization | 100.24% | 56.67% | 0.48% | -9.25% | -10.64% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.45% | 20.09% | 13.41% | 2.09% | 6.05% |
| Operating Income | -31.20% | -15.74% | -18.26% | 13.83% | 10.58% |
| Income Before Tax | -43.53% | -29.12% | -18.50% | 16.16% | 12.37% |
| Income Tax Expenses | -41.98% | 60.65% | -17.88% | 108.08% | 82.31% |
| Earnings from Continuing Operations | -44.04% | -47.84% | -18.72% | -80.76% | -0.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.04% | -47.84% | -18.72% | -80.76% | -0.12% |
| EBIT | -31.20% | -15.74% | -18.26% | 13.83% | 10.58% |
| EBITDA | -7.44% | -2.12% | -11.13% | 9.59% | 7.19% |
| EPS Basic | -43.80% | -47.75% | -18.86% | -81.02% | -0.27% |
| Normalized Basic EPS | -43.28% | -28.99% | -18.66% | 12.72% | 12.19% |
| EPS Diluted | -43.62% | -47.52% | -19.74% | -80.95% | 0.00% |
| Normalized Diluted EPS | -43.16% | -28.79% | -18.49% | 12.72% | 12.27% |
| Average Basic Shares Outstanding | -0.44% | -0.17% | 0.19% | 0.06% | 0.15% |
| Average Diluted Shares Outstanding | -0.65% | -0.45% | -0.01% | 0.06% | 0.10% |
| Dividend Per Share | 6.78% | 6.78% | 6.78% | 6.78% | 7.27% |
| Payout Ratio | 0.90% | 1.05% | 0.32% | 4.59% | 0.08% |